拜瑞妥能根治静脉血栓吗？

(Rivaroxaban) is a highly selective, oral drug that directly inhibits factor xa. By inhibiting factor xa, the endogenous and exogenous pathways of the coagulation cascade can be interrupted, and the generation of thrombin and thrombosis can be inhibited. Xarelto does not inhibit thrombin and has no proven effect on platelets. Clinically, Xarelto has gradually replaced warfarin as the anticoagulant drug of choice for venous thrombosis, atrial fibrillation, pulmonary embolism and other diseases. Today we will learn more about whether Xarelto can cure venous thrombosis?

In order to study the clinical effect of Xarelto (rivaroxaban) on the prevention and treatment of deep vein thrombosis (DVT) after severe traumatic brain injury (sTBI), a domestic study collected 157 sTBI patients who met the inclusion criteria, including 119 male patients (75.8%), aged (38.75±11.98) years old.

All patients were treated with intermittent intravenous pneumatic compression to prevent DVT, and D-dimer dynamic monitoring and regular ultrasound examination were used to screen for DVT. If the intracranial hemorrhage was stable, those whose D-dimer continued to decline 3 days after surgery and had high-risk factors were given prophylactic oral Xarelto. Patients with confirmed DVT were given therapeutic oral Xarelto (rivaroxaban). Xarelto was discontinued when the conditions for discontinuation were met. The patient's general information, dynamic changes in D-dimer, incidence of DVT, application of Xarelto and anticoagulant bleeding complications were retrospectively analyzed.

The results showed that no DVT was found by ultrasound in any of the patients whose D-dimer continued to decrease. There were 45 cases where D-dimer continued not to decrease or increased, and DVT was found in 43 cases by ultrasound. 47 cases (29.9%) took Xarelto prophylactically for 7 to 36 days (16.3±6.5), and no DVT occurred during the follow-up period; 43 cases (27.4%) took Xarelto for therapeutic treatment, and the course of treatment lasted 32 to 68 days (49.3±9.9). Only 1 case of peripheral DVT relapsed after stopping the drug.

There were no symptomatic pulmonary embolism and fatal bleeding complications. There were 3 cases of hematuria, 1 case of tracheotomy bleeding, and 1 case of hemorrhoids causing bloody stools. No increase in intracranial bleeding or other gastrointestinal bleeding was seen. It can be seen that patients can safely and effectively prevent and treat DVT after sTBI by applying Xarelto (rivaroxaban) anticoagulation.

Xarelto (rivaroxaban), produced by Bayer Healthcare GmbH, is mainly used clinically to prevent the formation of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients after hip and knee replacement surgery. It can also be used to prevent stroke and non-central nervous system embolism in patients with non-valvular atrial fibrillation, and reduce the risk of recurrence of coronary syndrome.

The above is the content of the therapeutic effect of (Rivaroxaban), I hope it can help you!

Recommended related hot articles: /newsDetail/76575.html